Protagonist Therapeutics, Inc
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| (c) | Trading Plans |
On June 30, 2026, Asif Ali, our Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to (i)73,214 shares of the Company’s common stock, (ii) 50% of the net shares issued to Mr. Ali after withholding taxes upon the vesting of restricted stock unit awards representing 21,346 shares of the Company’s common stock, and (iii) 50% of the net shares issued to Mr. Ali after withholding taxes upon the vesting of performance stock unit awards representing 12,800 shares of the Company’s common stock (assuming that such shares underlying performance stock units vest at target amounts) through September 30, 2027, or such earlier date when all transactions under the trading plan are completed, subject to certain conditions.
Except as discussed above, during the fiscal quarter ended June 30, 2026, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (in each case as defined in Item 408(a) of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.